Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.49 |
| ▸ | THRA | P10827 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740331 | 0.91 | THRA (0.52) | THRBTHRANPC1 | |
| SCHEMBL6735846 | 0.90 | THRA (0.53) | THRBTHRANPC1 | |
| SCHEMBL7061490 | 0.86 | THRA (0.56) | THRBTHRA | |
| SCHEMBL14488999 | 0.86 | THRB (0.50) | THRBTHRA | |
| SCHEMBL1642407 | 0.85 | THRA (0.58) | THRBTHRA | |
| SCHEMBL6661895 | 0.84 | THRA (0.67) | THRBTHRA | |
| SCHEMBL6742192 | 0.84 | THRA (0.52) | THRBTHRA | |
| SCHEMBL6738408 | 0.84 | THRA (0.51) | THRBTHRA | |
| SCHEMBL1641960 | 0.83 | THRA (0.48) | THRBTHRA | |
| SCHEMBL1642319 | 0.82 | THRA (0.59) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002540189-A | — | — | 2002-11-26 | — | — | JP | claimed |
| US-20020107390-A1 | Thyromimetic organic compounds | KUKKOLA PAIVI J (US) | 2002-08-08 | — | — | US | claimed |
| WO-2002032408-A2 | COMBINATIONS OF A THYROMIMETIC COMPOUND AND A STATIN | NOVARTIS AG (CH) | 2002-04-25 | — | — | WO | claimed |
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | claimed |
| EP-1165502-A1 | DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058279-A1 | DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-10-05 | — | — | WO | claimed |
| US-6790978-B2 | 4-HYDROXY-3-ARYLSULFONYL, 3-AMINOSULFONYL OR 3-AMINOCARBONYL-PHENOXYANILINOCARBONYL-OPTIONAL ALKYLENE-CARBOXYLIC ACID OR CARBONYL-5-TETRAZOLES | NOVARTIS AG (CH) | 2004-09-14 | — | — | US | disclosed |
| US-6599942-B1 | Method of lowering LDL cholesterol and Lipoprotein a levels in mammals using such compounds | NOVARTIS AG (CH) | 2003-07-29 | — | — | US | disclosed |
| US-20020107390-A1 | Thyromimetic organic compounds | KUKKOLA PAIVI J (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | disclosed |
| EP-1165502-A1 | DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058279-A1 | DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045751-A1 | Thyromimetic organic compounds | TPO, THRA, LPO | THRB 7/4885THRA 2/4885NPC1 318/4885 |
| US-20020107390-A1 | Thyromimetic organic compounds | TSHR, NR1H3, NR1H2 | THRB 5/4885THRA 4/4885NPC1 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.